New hope for rare liver cirrhosis combo: drug shows promise in small trial
NCT ID NCT06144086
First seen May 03, 2026 · Last updated May 18, 2026 · Updated 4 times
Summary
This study tested a drug called foscenvivint in 5 adults with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. The goal was to see if the drug could improve liver function and was safe. Participants received the drug and were monitored for 24 weeks. Results may help guide future treatment for this rare and complex condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, 113-8677, Japan
Conditions
Explore the condition pages connected to this study.